Tenaya Therapeutics disclosed preclinical data for its selective HDAC6 inhibitor TN‑301 during the Muscular Dystrophy Association’s Clinical & Scientific Conference held March 8‑11 2026. The presentation highlighted improvements in muscle performance and the correction of key drivers of Duchenne muscular dystrophy (DMD) cardiomyopathy in both in‑vitro and in‑vivo models.
In the mdx mouse model, TN‑301 administered at 3 mg/kg restored grip strength to wild‑type levels within five weeks, outperforming the approved pan‑HDAC inhibitor givinostat at 10 mg/kg. In human DMD iPSC‑derived cardiomyocytes, TN‑301 corrected disease‑associated phenotypes, suggesting a potential therapeutic benefit for DMD‑related cardiac dysfunction.
A Phase 1 safety study in healthy adults showed that TN‑301 was well tolerated across a wide dose range, with no serious adverse events, dose‑limiting toxicities, thrombocytopenia, or QT‑prolongation liabilities observed.
Tenaya plans to advance TN‑301 into clinical trials for heart failure with preserved ejection fraction (HFpEF) and DMD, positioning the compound as a dual‑indication candidate for both rare and prevalent cardiac and muscular conditions.
The presentation marked the first public disclosure of these preclinical findings, underscoring Tenaya’s progress toward clinical development and potential market differentiation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.